Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma
Numerous positron emission tomography (PET) targets for detection and staging of hepatocellular cancer have been developed in recent years. Hepatocellular carcinomas (HCCs) are clinically and pathologically heterogeneous tumours with a high tendency to be aggressive and unresponsive to chemotherapy....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/7/1975 |
| _version_ | 1797608268955123712 |
|---|---|
| author | Nozipho Nyakale Luca Filippi Colleen Aldous Mike Sathekge |
| author_facet | Nozipho Nyakale Luca Filippi Colleen Aldous Mike Sathekge |
| author_sort | Nozipho Nyakale |
| collection | DOAJ |
| description | Numerous positron emission tomography (PET) targets for detection and staging of hepatocellular cancer have been developed in recent years. Hepatocellular carcinomas (HCCs) are clinically and pathologically heterogeneous tumours with a high tendency to be aggressive and unresponsive to chemotherapy. Early detection is essential, and the need for an adequate imaging biomarker, which can overcome some of the limitations of conventional radiological imaging, is persistent. Flourine-18 (<sup>18</sup>F) flourodeoxyglucose (FDG), the most widely used PET radiopharmaceutical, has proven disappointing as a possible staple in the evaluation of HCC. This disappointment had led to experimentation with carious radiotracers, such as the choline derivatives, acetate, and prostate-specific membrane antigen, which appear to complement and/or enhance the role of FDG. In this study, we look at the various PET radiopharmaceuticals that have been used for imaging HCC and the particular pathways that they target in HCC and liver cancers. |
| first_indexed | 2024-03-11T05:42:10Z |
| format | Article |
| id | doaj.art-bb09241b3b6b40aeb486c556d082a02f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:42:10Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-bb09241b3b6b40aeb486c556d082a02f2023-11-17T16:24:19ZengMDPI AGCancers2072-66942023-03-01157197510.3390/cancers15071975Update on PET Radiopharmaceuticals for Imaging Hepatocellular CarcinomaNozipho Nyakale0Luca Filippi1Colleen Aldous2Mike Sathekge3Department of Nuclear Medicine, Sefako Makgatho Health Science University & Dr George Mukhari Academic Hospital, Pretoria 0208, South AfricaDepartment of Nuclear Medicine, Santa Maria Goretti Hospital, Via Canova 3, 04100 Latina, ItalyDepartment of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban 4058, South AfricaDepartment of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban 4058, South AfricaNumerous positron emission tomography (PET) targets for detection and staging of hepatocellular cancer have been developed in recent years. Hepatocellular carcinomas (HCCs) are clinically and pathologically heterogeneous tumours with a high tendency to be aggressive and unresponsive to chemotherapy. Early detection is essential, and the need for an adequate imaging biomarker, which can overcome some of the limitations of conventional radiological imaging, is persistent. Flourine-18 (<sup>18</sup>F) flourodeoxyglucose (FDG), the most widely used PET radiopharmaceutical, has proven disappointing as a possible staple in the evaluation of HCC. This disappointment had led to experimentation with carious radiotracers, such as the choline derivatives, acetate, and prostate-specific membrane antigen, which appear to complement and/or enhance the role of FDG. In this study, we look at the various PET radiopharmaceuticals that have been used for imaging HCC and the particular pathways that they target in HCC and liver cancers.https://www.mdpi.com/2072-6694/15/7/1975hepatocellular cancerpositron emission tomographyPETPSMACholineFDG |
| spellingShingle | Nozipho Nyakale Luca Filippi Colleen Aldous Mike Sathekge Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma Cancers hepatocellular cancer positron emission tomography PET PSMA Choline FDG |
| title | Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma |
| title_full | Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma |
| title_fullStr | Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma |
| title_full_unstemmed | Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma |
| title_short | Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma |
| title_sort | update on pet radiopharmaceuticals for imaging hepatocellular carcinoma |
| topic | hepatocellular cancer positron emission tomography PET PSMA Choline FDG |
| url | https://www.mdpi.com/2072-6694/15/7/1975 |
| work_keys_str_mv | AT noziphonyakale updateonpetradiopharmaceuticalsforimaginghepatocellularcarcinoma AT lucafilippi updateonpetradiopharmaceuticalsforimaginghepatocellularcarcinoma AT colleenaldous updateonpetradiopharmaceuticalsforimaginghepatocellularcarcinoma AT mikesathekge updateonpetradiopharmaceuticalsforimaginghepatocellularcarcinoma |